- Home
- NBIX vs DVA Comparison
NBIX vs DVA Comparison
Compare NBIX & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- DVA
- Stock Information
- Founded
- NBIX 1992
- DVA 1994
- Country
- NBIX United States
- DVA United States
- Employees
- NBIX N/A
- DVA N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- DVA Misc Health and Biotechnology Services
- Sector
- NBIX Health Care
- DVA Health Care
- Exchange
- NBIX Nasdaq
- DVA Nasdaq
- Market Cap
- NBIX 13.1B
- DVA 12.6B
- IPO Year
- NBIX 1996
- DVA 1995
- Fundamental
- Price
- NBIX $135.45
- DVA $149.77
- Analyst Decision
- NBIX Buy
- DVA Hold
- Analyst Count
- NBIX 23
- DVA 5
- Target Price
- NBIX $165.00
- DVA $153.40
- AVG Volume (30 Days)
- NBIX 910.2K
- DVA 658.8K
- Earning Date
- NBIX 02-05-2025
- DVA 02-11-2025
- Dividend Yield
- NBIX N/A
- DVA N/A
- EPS Growth
- NBIX 97.40
- DVA 41.03
- EPS
- NBIX 3.73
- DVA 9.24
- Revenue
- NBIX $2,242,800,000.00
- DVA $12,666,614,000.00
- Revenue This Year
- NBIX $27.07
- DVA $6.17
- Revenue Next Year
- NBIX $16.60
- DVA $3.56
- P/E Ratio
- NBIX $36.12
- DVA $16.13
- Revenue Growth
- NBIX 25.72
- DVA 6.34
- 52 Week Low
- NBIX $110.95
- DVA $103.40
- 52 Week High
- NBIX $157.98
- DVA $169.52
- Technical
- Relative Strength Index (RSI)
- NBIX 68.12
- DVA 38.07
- Support Level
- NBIX $125.61
- DVA $145.14
- Resistance Level
- NBIX $130.48
- DVA $156.74
- Average True Range (ATR)
- NBIX 2.92
- DVA 3.44
- MACD
- NBIX 0.72
- DVA -1.65
- Stochastic Oscillator
- NBIX 69.33
- DVA 21.28
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.